Diabetes tech stocks fell after the Centers for Medicare & Medicaid Services proposed a rule change that could alter reimbursement rates for continuous glucose monitors and insulin pumps. Tandem Diabetes Care slid 7.5%, Beta Bionics declined 4.3%, while Dexcom and Insulet both dropped over 4%.